Role of Fexofenadine in Diabetic Kidney Disease

Summary

* This study will that will be conducted on 60 outpatients previously diagnosed with type 2 diabetes mellitus. * Patients will be recruited from Internal Medicine Department, Tanta University Hospital, Tanta, Egypt. This study will be randomized, controlled, parallel, prospective clinical study. Accepted patients will be randomized into 2 groups as the following * Group 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six months * Group 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI plus fexofenadine tablets 60 mg once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after six months of treatment

Timeline

Start

2020-01-01

Primary completion

2022-02-01

Completion

2022-02-01

Publications

• El-Fatatry BM, El-Haggar SM, Ibrahim OM, Shalaby KH. Repurposing fexofenadine as a promising candidate for diabetic kidney disease: randomized clinical trial. Int Urol Nephrol. 2024 Apr;56(4):1395-1402. doi: 10.1007/s11255-023-03804-w. Epub 2023 Sep 23.

Drugs

Indications